1122
Today, Beijing Daxiang Technology Co., Ltd., a leader in the field of Organ-on-a-Chip in China, announced the completion of a round A financing of tens of millions of yuan. This round of financing is led byCDH VGC (CDH Innovation and Growth Fund), followed by Qiji Chuangtan Investment. At the same time, old shareholders such as Pharmaceuticals, Furong Investment, and Jiuyou Capital continue to increase their investment, which will mainly be used to accelerate the layout of the organ chip industry chain
Organ chip technology is a perfect combination of microfluidic technology and tissue engineering. Compared with traditional in vitro models, organ chip models can reproduce many key physiological characteristics of human organ, with better in vivo and in vitro consistency; At the same time, it can also to some extent solve the industry pain points of low clinical relevance caused by species differences in animal models. Currently, the US FDA and NIH are leading the "Clinical Trials on a Chip" initiative; The research and establishment of a testing center to conduct standardized testing of global organ chip products are expected to release relevant standards and guidelines in 2025; Many leading pharmaceutical companies in Europe and America have established the non-profit organization IQ Alliance (Innovation and Quality Consortium) to promote the standardized application of organ chips in drug research and development, and have carried out many cooperation projects with multiple organ chip companies
Da Xiang Technology is a member of the 2020 Qiji Innovation Forum Spring Camp, selected for the Merck China Innovation Center Accelerator, and has reached innovation cooperation with Merck. Since the launch of the first batch of domestically produced commercial organ chips in August 2020, Da Xiang Technology has built various pathological and physiological models on this basis, and has become the first organ chip company in China to cooperate with top foreign pharmaceutical companies in drug research and development projects, successfully achieving a closed-loop development, production, and salesDa Xiang Technology became the only Chinese organ chip company to be listed
At present, in addition to various models built with human primary cells, the technology platform of Daxiang Technology creatively combines the technologies of Organoid and Organon-a-Chip, and uses the advantages of both to launch theOrganoid on a-Chip platform to build a standardized, highly bionic, and controllable tumor microenvironment model, Solve the shortcomings of traditional organoid technology in application and implementation
”
